Sanofi India

Sanofi India reported a mixed Q4Current reported value: 4. No comparable prior figure is available in the source record. FY26 with domestic sales of ₹1,511 croreCurrent reported value: ₹1,511 crore. No comparable prior figure is available in the source record. for FY25, driven by 11% YoY growthCurrent 11% YoY growth. Reported change: +11% YoY. in the diabetes segment, led by insulin portfolio (Lantus, Toujeo, Soliqua). However, partnership revenue declined sharply to ₹153 croreCurrent ₹153 crore. Reported change: -24% QoQ. in Q4 from ₹200 crore in Q3 due to inventory phasing and a frozen period. PAT grew 4% YoYCurrent reported value: 4% YoY. No comparable prior figure is available in the source record. for the full year, but EBITDA margin fell to 21.5%Current reported value: 21.5%. No comparable prior figure is available in the source record., an eight-quarter low, impacted by export decline and partnership volatility. Management expects partnership fluctuations to continue through FY26, with stabilization by year-end. Diabetes growth remains robust, with insulin volume accelerating +6%Current +6%. Reported change: +6% YoY. overall and +11%Current +11%. Reported change: +11% YoY. in Q4. Key risk: continued partnership revenue volatility could mask underlying business performance.